

Docket No. 11-1265

**United States Court of Appeals for the District of Columbia Circuit
Americans for Safe Access, et al., Petitioners v.
Drug Enforcement Administration, Respondent**

**Certified Index of Material Comprising the Administrative Record
Drug Enforcement Administration (DEA)
Docket No. 352N**

A – Correspondence and Federal Register Notices

A.1- Transmittal letter and Petition to Reschedule Cannabis (Marijuana), by The Coalition for Rescheduling Cannabis (Coalition) dated 10/09/2002.

A.2- Letter of inquiry on status of review, by Coalition dated 02/11/2003.

A.3- Letter of acceptance to file, by the Drug Enforcement Administration (DEA) dated 04/03/2003.

A.4- Request for citations and translations of citations, by DEA dated 06/12/2003.

A.5- Letter of acknowledgement of receipt of request, by Coalition dated 06/23/2003.

A.6- Letter advising that materials requested are being gathered, by Coalition dated 07/30/2003.

A.7- Letter of response to request, with enclosures, by Coalition dated 09/09/2003 and note about letter.

A.8- Letter of inquiry on status of review, by Coalition dated 03/17/2004.

A.9- Request to the Department of Health and Human Services (DHHS) for scientific and medical evaluation and scheduling recommendation, and "Review of the Coalition for Rescheduling Cannabis's Petition to Repeal the Rules that Placed Marijuana in Schedule I of the Controlled Substances Act," by DEA dated 7/12/2004.

A.10- Letter of response and supporting document "Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act," by DHHS dated 12/06/2006.

A.11- Marijuana Scheduling Petition - Denial of Petition Drug, 54 Federal Register 249 (29 December 1989), pp 53767-53785,

A.12- Marijuana Scheduling Petition; Denial of Petition; Remand, 57 Federal Register 59 (26 March 1992), pp 10499-10509.

A.13- Denial of Petition; Notice, 66 Federal Register 75 (April 18, 2001), pp 20038-20076.

B- Materials referenced in the Petition to Reschedule Cannabis (Marijuana), Item A.1 on this list, and materials referenced in or included with Petitioner's Letter of response to request, Item A.7 on this list

If DEA requested a citation for, or translation of, material referenced in the Petition to Reschedule and the Petitioner provided none, then the material was not evaluated by DEA in its consideration of the petition. Internal DEA explanatory notes, listed in this index, were provided to the Administrator to explain these omissions and any substitutions of material.

** Denotes that document cited appears in more than one part of the record. Corresponding cross-references in this list appear in parentheses.*

+ Denotes correction to the citation that appears in the record documents.

B.1- Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. *Life Sci* 1995;56(23-24):2097-102.

B.2- Abrams DI, et al. Short-Term Effects of Cannabinoids In Patients With HIV Infection. *J Cannabis Ther* 2002;2(2):92-93.

B.3- Adami M, Frati P, Bertini S, Kulkarni-Narla A, Brown DR, de Caro G, Coruzzi G, Soldani G. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. *Br J Pharmacol* 2002;135(7):1598-606.

B.4- Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. *FASEB J* 2001;15(2):300-2.

B.5- DEA internal note to the Administrator about omission of about Barsch G et al. (1996) because Petitioner did not provide a translation.

B.6- Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *J Pain Symptom Manage* 1995;10(2):89-97.

B.7- Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. *J Pain Symptom Manage* 1997; 14(1): 7-14.

B.8- Berger A. Marijuana has potential for misuse. *BMJ* 2000;321:979.

+B.9- Berkley KJ, Dmitrieva N. Influence of synthetic cannabinoid ligands on the rat bladder and uterus: clinical implications. 2001 Congress on Cannabis and the Cannabinoids, Berlin, Germany, International Association for Cannabis as Medicine, p. 8.

B.10- Berrendero F, Sanchez A, Cabranes A, Puerta C, Ramos JA, Garcia-Merino A, Fernandez-Ruiz J. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. *Synapse* 2001;41(3):195-202.

B.11- Biegon A, Kerman IA. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. *Neuroimage* 2001;14(6):1463-8.

+B.12- Blank D, Fenton J. Early pre-employment testing for marijuana: Demographic and employee retention patterns. In: Gust S, Walsh M, eds. *Drugs in the workplace: Research and evaluation data*. Rockville (MD): NIDA, 1989:139-150.

B.13- Note about Brady CM et al. (2001; 2003). DEA requested a copy of the 2001 reference, a conference abstract, from the petitioner in a letter dated 06/12/03. In a response dated 09/09/03, the petitioner provided a copy of a 2003 abstract by the same author. DEA subsequently located a copy of the 2001 reference. Both are included in the record.

+B.14- Brady CM, DasGupta R, Wiseman OJ, Berkley KJ, Fowler CL. Acute and chronic effects of cannabis based medicinal extract on refractory lower urinary tract dysfunction in patients with advanced multiple sclerosis - early results. 2001 Congress on Cannabis and the Cannabinoids, Berlin, Germany: International Association for Cannabis as Medicine, p. 9.

B.15- Brady C, DasGupta R, Wiseman O, Berkley K, Fowler C. Sublingual cannabis based medicinal extracts for bladder Dysfunction in advanced multiple sclerosis. *International Cannabinoid Research Society 2003 - Symposium On The Cannabinoids*, June 25 - 28, 2003, Cornwall, Ontario, p. 56.

B.16- Braun BL, Hannan P, Wolfson M, Jones-Webb R, Sidney S. Occupational attainment, smoking, alcohol intake, and marijuana use: ethnic-gender differences in the CARDIA study. *Addict Behav* 2000;25(3):399-414.

B.17- Braun BL, Tekawa IS, Gerberich SG, Sidney S. Marijuana use and medically attended injury events. *Ann Emerg Med* 1998;32(3 Pt 1):353-360.

*B.18- Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. *Mol Pharmacol* 2001; 60(1): 155-63. (same as C.23-).

B.19- Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. *Int J Clin Pharmacol Ther* 1996; 34(10): 446-52.

- B.20- British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers, 1997.
- B.21- Brody S, Preut R. Cannabis, tobacco, and caffeine use modify the blood pressure reactivityprotection of ascorbic acid. *Pharmacol Biochem Behav* 2002;72(4):811-6.
- B.22- Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. *Biochim Biophys Acta* 2001; 1538(2-3): 252-9.
- B.23- Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. *Nature* 2000; 408(6808): 96-101.
- B.24- Carley DW, Paviovic S, Janelidze M, Radulovacki M. Functional role for cannabinoids in respiratory stability during sleep. *Sleep* 2002;25(4):391-8.
- B.25- Carter GT, Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. *Am J Hosp Palliat Care* 2001;18(4):264-70.
- B.26- DEA internal note to the Administrator about Petitioner's substitution of B.27 and B.28 for Casanova ML et al. (2001).
- +B.27- Casanova ML, Blázquez C, Fernández-Acenero MJ, Villanueva C, Jorcano J, Guzmán M. Cb1 and CB2 receptors are expressed in the skin and their activation inhibits the growth of skin cancer cells. 2001 ICRS Symposium on the Cannabinoids, Euroforum Infantes, San Lorenzo de El Escorial, Spain, International Cannabinoid Research Society, p 151.
- B.28- Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Acenero MJ, Huffman JW, Jorcano JL, Guzmán M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *J. Clin. Invest.* 2003;111:43–50.
- B.29- Chen K, Kandel DB, Davies M. Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. *Drug Alcohol Depend* 1997 Jun 6;46(1-2):53-67.
- B.30- Cheshier G, Longo M. Cannabis and Alcohol in Motor Vehicle Accidents. In: Grotenhermen F, Russo E, eds. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton NY: Haworth Press, 2002.
- B.31- Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. *J Pharmacol Exp Ther* 1999;289(2):859-67.
- B.32- Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. *Annals of Neurology* 1983;13:669-671.

- B.33- Cocoran, M.E. and Z. Amit. 1974. Reluctance of rats to drink hashish suspensions: free choice and forced consumption, and the effects of hypothalamic stimulation. *Psychopharmacologia* 35:129-47. Cited in Felder and Glass 1998.
- B. 34- College on the Problems of Drug Dependence, Statement on National Drug Policy, March 1997.
- B.35- Committee on Opportunities in Drug Abuse Research, Institute of Medicine. National Academy Press. Washington, D.C. 1996.
- B.36- DEA internal note to the Administrator about Petitioner's substitution of B.37 for Consroe P. et al. (1998).
- B.37- Consroe P. Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders *Neurobiology of Disease* 1998; 5:534-551.
- B.38- Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. *Eur Neurol* 1997;38(1):44-8.
- B.39- Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. *Br J Pharmacol* 2002;135(1):181-7.
- B.40- Cotts C. Marijuana made easy. *The Nation*, September 20, 1999.
- B.41- Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. *Int J Clin Pharmacol Biopharm* 1979; 17(5): 191-6.
- B.42- Crowley TJ Macdonald MJ Whitmore EA Mikulich SK. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. *Drug Alcohol Depend* 1998;50(1):27-37.
- B.43- Dansak DA. As an antiemetic and appetite stimulant in cancer patients. In: Mathre ML, ed. *Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana*. Jefferson/NC: McFarland & Co, 1997, pp. 69-83.
- B.44- Darmani NA. Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. *Neuropsychopharmacology* 2001;24(2):198-203.
- B.45- Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. *Pharmacol Biochem Behav* 2001; 69(1-2): 239-49.

- B.46- Darmani NA. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannabinoids. *J Pharmacol Exp Ther* 2002;300(1):34-42.
- B.47- De Petrocellis L, Melck D, Bisogno T, Di Marzo V, Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. *Chem Phys Lipids* 2000; 108(1-2): 191-209.
- B.48- De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. *Neuroscience* 1999; 92(1): 377-87.
- B.49- Degenhardt L, Hall W, Lynskey M. Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. *Addiction* 2001;96(11):1603-14.
- B.50- Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. *Psychol Med* 2001;31(4):659-68.
- B.51- Degenhardt L, Hall W. The relationship between tobacco use, substance-use disorders and mental health: results from the National Survey of Mental Health and Well-being. *Nicotine Tob Res* 2001;3(3):225-34.
- B.52- Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR, Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptormediated actions of anandamide in mouse brain. *J Neurochem* 2000; 75(6): 2434-44.
- B.53- Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. *Nature* 2001;410(6830):822-5.
- B.54- Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. *Biochem J* 2001;358(Pt 1):249-55.
- B.55- Elsner F, Radbruch L, Sabatowski R. Tetrahydrocannabinol zur Therapie chronischer Schmerzen [Tetrahydrocannabinol for treatment of chronic pain]. *Schmerz* 2001; 15(3): 200-4.
- B.56- DEA internal note to the Administrator about inclusion of item B.55 and B.57.
- B.57- Translation to English of abstract of document B. 55.

B.58- Farquhar-Smith WP, Rice AS. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. *Anesthesiology* 2001;94(3):507-13.

B.59- Felder, Christian, and Michelle Glass. 1998. Cannabinoid receptors and their endogenous agonists. *Annual Review of Pharmacology and toxicology*, 38:179-200.

B.60- DEA internal note to the Administrator about omission of Fortissimo I (2002) because Petitioner did not provide a translation. DEA requested a copy of this reference from the petitioner in a letter dated 06/12/03. In a response dated 09/09/03, the petitioner stated it could not provide a translation for this reference, and didn't provide a copy of this reference. It was therefore not evaluated.

B.61- Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. *Pain* 2001;92(1-2):91-100.

B.62- Fride E. Cannabinoids and cystic fibrosis: a novel approach to etiology and therapy. *J Cannabis Ther* 2002;2(1):59-71.

*B.63- Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. *CMAJ* 2002;166(7):887- 91 (same as C59-).

+B.64- Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M: Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and ERK activation. *Nature Medicine* 2000;6:313-319.

B.65- Gieringer D. Cannabis "vaporization": a promising strategy for smoke harm reduction. *J Cannabis Ther* 2001;1(3-4):153-170.

B.66- Gieringer D. Medical Use of Cannabis: Experience in California. In *Cannabis and Cannabinoids. Pharmacology, Toxicology, and Therapeutic Potential*, edited by F. Grotenhermen and E. Russo. Binghamton (NY): Haworth Press, 2002.

+B.67- Gieringer D. The Acceptance of Medicinal Marijuana in the U.S. *J Cannabis Ther* 2003;3(1):53-65.

B.68- Gilson I, Busalacchi M. Marijuana for intractable hiccups. *Lancet* 1998; 351(9098): 267.

B.69- Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. *J Pharmacol Exp Ther* 2001; 298(1): 7-14.

B.70- Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat Neurosci* 1999;2(4):358-63.

B.71- Glass M. The role of cannabinoids in neurodegenerative diseases. *Prog Neuropsychopharmacol Biol Psychiatry* 2001;25(4):743-65.

*B.72- Golub A, Johnson BD. Variation in youthful risks of progression from alcohol and tobacco to marijuana and to hard drugs across generations. *Am J Public Health* 2001;91(2):225-32 (same as C.66-).

B.73- Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. *Epilepsia* 2001; 42(10): 1266-72.

B.74- Gorman DM, Derzon JH. Behavioral traits and marijuana use and abuse: a meta-analysis of longitudinal studies. *Addict Behav* 2002;27(2):193-206.

B.75- Green K, Kears EC, McIntyre OL. Interaction between delta-9-tetrahydrocannabinol and indomethacin. *Ophthalmic Res* 2001;33(4):217-20.

B.76- Griffin KW, Botvin GJ, Scheier LM, Nichols TR. Factors associated with regular marijuana use among high school students: a long-term follow-up study. *Subst Use Misuse* 2002;37(2):225-38.

B.77- Grinspoon L, Bakalar JB. *Marihuana, the forbidden medicine*. New Haven: Yale University Press, 1993.

B.78- Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. *J Psychoactive Drugs* 1998; 30(2): 171-7.

B.79- Grotenhermen F, Russo E, editors. *Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential*. Binghamton NY: Haworth Press, 2002a.

B.80- Grotenhermen F. Harm reduction associated with inhalation and oral administration of cannabis and THC. *J Cannabis Ther* 2001;1(3-4):133-152.

+*B.81- Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokin*, 2003, 42(4):327-360 (same as C.73-).

B.82- Grotenhermen F. Review of therapeutic effects. In: Grotenhermen F, Russo E, editors. *Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential*. Binghamton NY: Haworth Press, 2002: 123-42.

B.83- Grotenhermen F. Review of unwanted actions of Cannabis and THC. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton NY: Haworth Press, 2002: 233-48.

+B.84- Grotenhermen F. The medical use of cannabis in Germany. *J Drug Issues* 2002, 32:607-633.

B.85- Gunderson EW, Vosburg SK, Hart CL. Does marijuana use cause long-term cognitive deficits? *JAMA* 2002;287(20):2652.

B.86- Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. *J Mol Med* 2001; 78(11): 613-25.

+B.87- Hagenbach U, Ghafoor N, Brenneisen R, Luz S, Maeder M. Clinical investigation of Δ^9 -tetrahydrocannabinol (THC) as an alternative therapy for overactive bladders in spinal cord injury (SCI) patients. 2001 Congress on Cannabis and the Cannabinoids, Berlin, Germany: International Association for Cannabis as Medicine, p. 10.

B.88- Hall W, Room R, Bondy S. Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In: Kalant H, Corrigan W, Hall W, Smart R, eds. The health effects of cannabis. Toronto: Addiction Research Foundation, 1999, pp. 477-508.

B.89- Hampson A. Cannabinoids as neuroprotectants against ischemia. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 101-10.

B.90- Harris, R.T., W. Waters and D. McLendon. 1974. Evaluation of reinforcing capability of Δ^9 -tetrahydrocannabinol in rhesus monkeys. *Psychopharmacologia* 37:23-29. Cited in Felder & Glass, 1998.

B.91- Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. *Neuropsychopharmacology* 2001;25(5):757-65.

B.92- Hartley JP, Nogrady SG, Seaton A. Bronchodilator effect of delta1-tetrahydrocannabinol. *Br J Clin Pharmacol* 1978; 5(6): 523-5.

B.93- Helliwell, D.: GPs are key informants in medicinal cannabis survey. *GP Speak, Newsletter of the Northern Rivers Division of General Practice*, April 1999, S.4.

B.94- Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. *J Psychopharmacol* 1993; 7: 389-91.

B.95- Henningfeld JE, In: Hilts PJ. Is Nicotine Addictive? It Depends on Whose Criteria You Use. *New York Times*, August 2, 1994.

- B.96- Hepler RS, Frank IR. Marijuana smoking and intraocular pressure. JAMA 1971; 217(10): 1392
- B.97- Hepler RS, Petrus RJ. Experiences with administration of marijuana to glaucoma patients. In: Cohen S, Stillman RC, editors. The therapeutic potential of marijuana. New York: Plenum Medical Book, 1976: 63-75.
- B.98- Hoey J. Marijuana: federal smoke clears, a little. CMAJ 2001;164(10):1397.
- B.99- Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-488.
- B.100- Holden, Gwen A. A Guide to State Controlled Substances Acts. National Criminal Justice Association, January, 1991. Prepared in cooperation with the U.S. Department of Justice, Bureau of Justice Assistance and the National District Attorney's Association, American Prosecutors Research Institute. National Institute of Justice Call Number: 132321.
- B.101- Hollister L. Marijuana (cannabis) as medicine. J Cannabis Ther 2001;1(1):5-27.
- B.102- House of Lords Select Committee on Science and Technology. Cannabis. The scientific and medical evidence. London: The Stationery Office, 1998.
- B.103- House of Lords Select Committee on Science and Technology. Therapeutic Uses of Cannabis. 2nd Report, Session 2000-2001, London 2001.
- B.104- Inserm. Cannabis - quels effets sur le comportement et la santé ? Paris: Les éditions Inserm, 2001.
- B.105- Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G, Mascolo N, Di Marzo V, Capasso F. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134(3): 563- 70.
- B.106- Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001;1(6):597-603.
- B.107- Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, Capasso F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000; 129(8): 1627-32.
- B.108- Jacobson SW, Chiodo LM, Sokol RJ, Jacobson JL. Validity of maternal report of prenatal alcohol, cocaine, and smoking in relation to neurobehavioral outcome. Pediatrics 2002;109(5):815-25.

- B.109- Jacobsson SO, Wallin T, Fowler CJ. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. *J Pharmacol Exp Ther* 2001; 299(3): 951-9.
- B.110- Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol* 2002;20(2):567-73.
- B.111- Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, Simone DA. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. *Pain* 2001;93(3):303-15.
- *B.112- Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine: Assessing the science base. Washington DC: Institute of Medicine, National Academy Press, 1999 (same as C.93-).
- B.113- Kandel D, Chen K, Warner LA, Kessler RC, Grant B. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population. *Drug Alcohol Depend* 1997 Jan 10;44(1):11-29.
- B.114- Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. *Neurology*. 2002;58(9):1323-4.
- B.115- Kleiber D, Soellner R, Tossmann P. Cannabiskonsum in der Bundesrepublik Deutschland: Entwicklungstendenzen, Konsummuster und Einflußfaktoren. Bonn: Bundesministerium für Gesundheit, 1997.
- +B.116- Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. *Crit Care Med* 2002;30(3):548-554. 710-1.
- B.117- Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. *Exp Clin Psychopharmacol* 2000;8(4):483-92.
- B.118- Lagneux C, Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. *Br J Pharmacol* 2001;132(4):793-6.
- B.119- Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, Salva K, Wiernik PH, Holroyde CP, Hammill S, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. *J Pain Symptom Manage* 1991; 6(6): 352-9.
- B.120- Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Perez-Rosado A, Manzanares J, Ramos JA, Fernandez-Ruiz J. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. *Synapse* 2002;44(1):23-35.

- B.121- Leite, J.R. and E.A. Carlina. 1974. Failure to obtain cannabis-directed behavior and abstinence syndrome in rats chronically treated with cannabis sativa extracts. *Psychopharmacologia* 36:133-45. Cited in Felder and Glass 1998.
- B.122- Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. *Neuroreport* 1999;10(8):1665-9.
- B.123- Lichtman AH, Sheikh SM, Loh HH, Martin BR. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. *J Pharmacol Exp Ther* 2001p;298(3):1007-14.
- B.124- Lowenstein SR, Koziol-McLain J. Drugs and traffic crash responsibility: a study of injured motorists in Colorado. *J Trauma* 2001;50(2):313-20.
- *B.125- Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65 years of age. *Am J Epidemiol* 1999;149(9):794-800 (same as C.108-).
- B.126- Mackesy-Amiti ME, Fendrich M, Goldstein PJ. Sequence of drug use among serious drug users: typical vs atypical progression. *Drug Alcohol Depend* 1997;45(3):185-96.
- B.127- Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. *Lancet* 1995; 345(8949):579.
- B.128- Mathre ML, editor. Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson, NC: McFarland & Co, 1997.
- B.129- Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. *European Archives of Psychiatry and Clinical Neuroscience* 1990;240:1-4.
- B.130- McDaniel M. Does pre-employment drug use predict on-the-job suitability? *Personnel Psychology* 1988;41:717-729.
- B.131- McGregor, I.S., C.N. Issakidis, and G. Prior. 1996. Adverse effects of the synthetic cannabinoid CP55,940 in rats. *Pharmacol. Biochem. Behav.* 53:657-64. Cited in Felder and Glass 1998.
- B.132- McGregor, I.S., P.A. Bryant, and J. Arnold. 1995. CP55,940, a synthetic cannabinoid, does not sensitize locomotor activity or cocaine responsitivity with intermittent administration in Wistar rats. *Soc. Neurosci. Abstr.* 21:726. Cited in Felder and Glass 1998.
- B.133- Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press, 1986.

- B.134- Mechoulam R, Shohami E. HU-211: Cannabinoid Neuroprotective Agent. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 389-400.
- B.135- Meinck HM, Schönle PWA, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. *Journal of Neurology* 1989;236:120-122.
- B.136- Melamed R. Possible mechanisms in autoimmune diseases. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 111-122.
- B.137- Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marijuana on intraocular and blood pressure in glaucoma. *Ophthalmology* 1980; 87(3): 222-8.
- B.138- Merritt JC, Olsen JL, Armstrong JR, McKinnon SM. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. *J Pharm Pharmacol* 1981; 33(1): 40-1.
- B.139- Mikulich SK, Hall SK, Whitmore EA, Crowley TJ. Concordance between DSM-III-R and DSM-IV diagnoses of substance use disorders in adolescents. *Drug Alcohol Depend* 2001;61(3):237-48.
- B.140- Mikuriya TH. Cannabis substitution. An adjunctive therapeutic tool in the treatment of alcoholism. *Med Times* 1970; 98(4): 187-91.
- B.141- Miller P, Plant M. Heavy cannabis use among UK teenagers: an exploration. *Drug Alcohol Depend* 2002;65(3):235-42.
- B.142- Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. *Circulation* 2001;103(23):2805-9.
- B.143- Monhemius R, Azami J, Green DL, Roberts MH. CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. *Brain Res* 2001;908(1):67-74.
- B.144- Morris MC, Evans DA, Hebert LE, Bienias JL. Methodological issues in the study of cognitive decline. *Am J Epidemiol* 1999;149(9):789-93.
- B.145- Mueller-Vahl KR, Kolbe H, Schneider U, Emrich H M: Cannabis in Movement Disorders. In: Grotenhermen F, Saller R (eds): Cannabis und Cannabinoide in der Medizin [Cannabis and Cannabinoids in Medicine]. *Research in Complementary Medicine* 6, Supplement 3, 1999b.
- B.146- Mueller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Movement Disorders. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 205-214.

B.147- Mueller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM. Treatment of Tourette-Syndrome with delta-9-tetrahydrocannabinol (THC): a randomized crossover trial. *Pharmacopsychiatry* 2002;35(2):57-61.

B.148- Mueller-Vahl KR, Schneider U, Kolbe H, Emrich HM: Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. *Am J Psychiatry* 156:3, 1999a.

B.149- Mueller-Vahl, K.R., Kolbe, H., Dengler, R.: Gilles de la Tourette-Syndrom. Einfluß von Nikotin, Alkohol und Marihuana auf die klinische Symptomatik. *Nervenarzt* 1997;68:985-989.

B.150- Internal DEA note to the Administrator about omission of (#) Mueller-Vahl reference because Petitioner did not provide a translation, Petitioner's substitution of B.145 for one foreign language item and Petitioner's inclusion of B.151.

B.151- Mueller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Treatment of Tourette Syndrome with Delta-9Tetrahydrocannabinol (delta9-THC): No Influence on Neuropsychological Performance. *Neuropsychopharmacology* (2003) 28, 384-388.

+B.152- Musty R, Deyo R. Effects of a cannabis extract in animal tests of depression, spasticity and antinoception: a preliminary report. 2001 Congress on Cannabis and the Cannabinoids, Berlin, Germany, International Association for Cannabis as Medicine, p.1.

B.153- Musty RE, Rossi R. Effects of smoked cannabis and oral Δ_9 -tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. *J Cannabis Ther* 2001;1(1):29-42.

B.154- Nofziger L. Foreword. In: *Marijuana RX - The Patients Fight for Medicinal Pot*, edited by Robert C Randall and Alice M O'Leary, 1999.

B.155- Normand J, Salyards S, Mahoney J. An evaluation of preemployment drug testing. *J Appl Psychol* 1990;75:629-639.

+B.156- Notcutt W, Price M, Miller R, Newport S, Sansom C, Simmonds S. Medicinal cannabis extracts in chronic pain: (2) comparison of two patients with back pain and sciatica. 2001 Congress on Cannabis and the Cannabinoids, Berlin, Germany: International Association for Cannabis as Medicine, p. 25.

+B.157- Notcutt W, Price M, Miller R, Newport S, Sansom C, Simmonds S. Medicinal cannabis extracts in chronic pain: (3) comparison of two patients with multiple sclerosis. 2001 Congress on Cannabis and the Cannabinoids, Berlin, Germany: International Association for Cannabis as Medicine, p. 26.

+B.158- Notcutt W, Price M, Miller R, Newport S, Sansom C, Simmonds S. Medicinal cannabis extracts in chronic pain: (4) cannabidiol modification of psycho-active effects in Δ_9 -THC. 2001

Congress on Cannabis and the Cannabinoids, Berlin, Germany: International Association for Cannabis as Medicine, p. 27.

+B.159- Notcutt W, Price M, Miller R, Newport S, Sansom C, Simmonds S. Medicinal cannabis extracts in chronic pain: (5) cognitive function and blood cannabinoid levels. 2001c Congress on Cannabis and the Cannabinoids, Berlin, Germany: International Association for Cannabis as Medicine, p. 28.

B.160- Noyes R Jr, Brunk SF, Avery DAH, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. *Clin Pharmacol Ther* 1975a; 18(1): 84-9.

B.161- Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. *J Clin Pharmacol* 1975b; 15(2-3): 139-43.

B.162- Noyes R, Baram DA. Cannabis analgesia. *Comprehensive Psychiatry* 1974;15:531-535.

B.163- Nyquist JR. Does marijuana use cause long-term cognitive deficits? *JAMA* 2002;287(20):2652.

B.164- Ogborne AC, Smart RG, Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. *CMAJ* 2000;162:1685-1686.

B.165- Onaivi, E.S., M.R. Green, and B.R. Martin. 1990. Pharmacological characterization of cannabinoids in the elevated plus maze. *J Pharmacol. Exp. Ther.* 253:1002-9. Cited in Felder and Glass 1998.

B.166- Parish DC. Relation of the pre-employment drug testing result to employment status: a oneyear follow-up. *J Gen Intern Med* 1989;4(1):44-47.

B.167- Parker LA, Kemp SW. Tetrahydrocannabinol (THC) interferes with conditioned retching in *Suncus murinus*: an animal model of anticipatory nausea and vomiting (ANV). *Neuroreport* 2001;12(4):749-751.

B.168- Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. *Neuroreport* 2002 Apr 16;13(5):567-70.

B.169- Parker, L.A. and T. Gilles. 1995. THC-induced place and taste aversion in Lewis and Sprague-Dawley rats. *Behav. Neurosci.* 109:71-78. Cited in Felder and Glass 1998.

B.170- Peretti-Watel P, Beck F, Legleye S. Beyond the U-curve: the relationship between sport and alcohol, cigarette and cannabis use in adolescents. *Addiction* 2002;97(6):707-16.

- B.171- Pertwee RG. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. *Life Sci* 1999; 65: 597- 605.
- B.172- Pertwee RG. Prescribing cannabinoids for multiple sclerosis. *CNS Drugs* 1999;11(5):327- 334.
- B.173- Pertwee RG. Sites and Mechanisms of Action. In: Grotenhermen F, Russo E, editors. *Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential*. Binghamton (NY): Haworth Press, 2002: 73-88.
- B.174- Petro DJ, Ellenberger C Jr. Treatment of human spasticity with delta 9-tetrahydrocannabinol. *J Clin Pharmacol* 1981; 21(8-9 Suppl): 413S-6S.
- B.175- Petro DJ. Marijuana as a therapeutic agent for muscle spasm or spasticity. *Psychosomatics* 1980; 21(1): 81, 85.
- B.176- Plane F, Holland M, Waldron GJ, Garland CJ, Boyle JP. Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. *Br J Pharmacol* 1997;121(8):1509-11.
- B.177- Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. *Pharmacology, Biochemistry and Behavior* 1991;40:695-700.
- B.178- Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. *Arch Gen Psychiatry* 2001;58(10):909-15.
- B.179- Pope HG Jr. Cannabis, cognition, and residual confounding. *JAMA* 2002;287(9):1172-4.
- B.180- Porcella A, Maxia C, Gessa GL, Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. *Eur J Neurosci* 2001;13(2):409-12.
- B.181- Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. *Pharmacol Ther* 2001;90(1):45-60.
- B.182- Price RK, Risk NK, Spitznagel EL Remission from drug abuse over a 25-year period: patterns of remission and treatment use. *Am J Public Health* 2001 Jul;91(7):1107-13.
- B.183- Ralevic V, Kendall DA. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. *Eur J Pharmacol* 2001; 418(1-2): 117-25.

B.184- Randall MD, Kendall DA. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. *Eur J Pharmacol* 1997;335(2- 3):205-9.

B.185- Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure. Effects on neuropsychological outcomes at 10 years. *Neurotoxicol Teratol* 2002;24(3):309-20.

B.186- Robson P. Therapeutic aspects of cannabis and cannabinoids. *Br J Psychiatry* 2001;178:107- 15.

B.187- Internal DEA note to the Administrator about substitution of B.187 for Roques B. (1998) and inclusion of English translation of excerpt referenced by the Petitioner as B.188.

+B.188- Roques B. Problemes posées par la dangerosité des drogues. Introduction and Chapter 10, *Le Cannabis*. Rapport du professeur Bernhard Roques au Secrétaire d'Etat à la Santé. Paris, 1998.

B. 189- Translation to English of Chapter 10 of B. 188, as described in B.187.

B.190- Russo E, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, Kirlin KA. Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis. *J Cannabis Ther* 2002;2(1):3-58.

B.191- Russo E. Hemp for Headache: An In-Depth Historical and Scientific Review of Cannabis in Migraine Treatment. *J Cannabis Ther* 2001;1(2):21-92.

B.192- Ryan J, Zwerling C, Jones M. The effectiveness of preemployment drug screening in the prediction of employment outcome. *J Occup Med* 1992;34(11):1057-1063.

B.193- Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. *N Engl J Med* 1980; 302(3): 135-8.

B.194- Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S, Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. *Cancer Res* 2001; 61(15): 5784-9.

B.195- Sandyk R, Awerbuch G. Marijuana and Tourette's syndrome. *J Clin Psychopharmacol* 1998; 8: 844.

B.196- Schnelle M, Grotenhermen F, Reif M, Gortler RW. Ergebnisse einer standardisierten Umfrage zur medizinischen Verwendung von Cannabisprodukten im deutschen Sprachraum, [Results of a standardized survey on the medical use of cannabis products in the

Germanspeaking area]. 1999; (Suppl 3) 28-36. *Forsch Komplementarmed [Res Complementary Med]* 1999; (Suppl 3) 28-36.

B.197- Schwartz RH. Marijuana: a decade and a half later, still a crude drug with underappreciated toxicity. *Pediatrics* 2002;109(2):284-9.

B.198- See, G. 1890. Anwendung der Cannabis indica in der Behandlung der Neurosen und gastrischen Dyspepsieen. *Dtsch Med Wschr* 60(31-34):679-682.

B.199- See, G. 1890. Anwendung der Cannabis indica in der Behandlung der Neurosen und gastrischen Dyspepsieen. *Dtsch Med Wschr* 60(31-34): 727-730.

B.200- See, G. 1890. Anwendung der Cannabis indica in der Behandlung der Neurosen und gastrischen Dyspepsieen. *Dtsch Med Wschr* 60(31-34): 748-754.

B.201- See, G. 1890. Anwendung der Cannabis indica in der Behandlung der Neurosen und gastrischen Dyspepsieen. *Dtsch Med Wschr* 60(31-34): 771- 774.

B.202- Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. *Eur J Pharmacol* 2001; 415(1): R5-R7.

B.203- Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. *Neurology* 2001; 57(11): 2108-11.

B.204- Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. *Anesthesiology* 2001;94(5):882-7.

B.205- Smiley AM: Marijuana: on road and driving simulator studies. In: Kalant H, Corrigal W, Hall W, Smart R, eds. *The Health Effects of Cannabis*. Toronto: Addiction Research Foundation, 1999:173-191.

B.206- Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. *Addiction* 2002;97(6):621-32.

B.207- Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. *Pharmacol Biochem Behav* 2001;69(3-4):343-50.

B.208- Solowij N, Stephens R, Roffman RA, Babor T. Does marijuana use cause long-term cognitive deficits? *JAMA* 2002;287(20):2653-4.

B.209- Stamer WD, Golightly SF, Hosohata Y, Ryan EP, Porter AC, Varga E, Noecker RJ, Felder CC, Yamamura HI. Cannabinoid CB(1) receptor expression, activation and detection of

endogenous ligand in trabecular meshwork and ciliary process tissues. *Eur J Pharmacol* 2001;431(3):277-86.

B.210- Stanley-Cary CC, Harris C, Martin-Iverson MT. Differing effects of the cannabinoid agonist, CP 55,940, in an alcohol or Tween 80 solvent, on prepulse inhibition of the acoustic startle reflex in the rat. *Behav Pharmacol* 2002;13(1):15-28.

B.211- Stinchcomb A, Challapalli P, Harris K, Browe J. Optimization of in vitro experimental conditions for measuring the percutaneous absorption of Δ^9 -THC, cannabidiol, and WIN55,212-2. 2001 Symposium on the Cannabinoids. Burlington Vermont: International Cannabinoid Research Society, 2001, abstr. 161.

B.212- Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. *Addiction* 2001;96(5):737-48.

B.212- Swift W, Hall W, Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. *Drug Alcohol Depend* 2001;63(2):147-53.

B.213- Takahashi, R.N. and G. Singer. 1981. Cross self-administration of Δ^9 -tetrahydrocannabinol and d-amphetamine in rats. *Braz. J. Med. Biol. Res.* 14:395-400. 1981. Cited in Felder and Glass 1998.

*B.214- Tanda G, Munzar P, Goldberg SR Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci* 2000;3(11):1073-4 (same as C.141-).

B.215- Tanda, G., F.E. Pontieri and G. Di Chiara. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common opiod receptor mechanism. *Science.* 276: 2048 - 2050. Cited in Califiano, 1998. Cited in Felder and Glass 1998.

B.216- Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral Δ^9 -tetrahydrocannabinol on specific airway conductance in asthmatic subjects. *Am Rev Respir Dis* 1974; 109(4): 420-8.

B.217- TNO Preventie en Gezondheid: Aard en omvang van Cannabis gebruik bij mensen met Multiple Sclerose. 1998, ISBN 9067435171.

B.218- Tyler K, Hillard CJ, Greenwood-Van Meerveld B. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. *Eur J Pharmacol* 2000;409(2):207-11.

B.219- Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. *Adv Alcohol Subst Abuse* 1987; 7(1): 39-50.

B.220- Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. *Eur J Neurosci* 2001;13(9):1816-24.

B.221- van der Stelt M, Veldhuis WB, van Haafden GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegthart JF, Di Marzo V, Nicolay K. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. *J Neurosci* 2001;21(22):8765-71.

B.222- Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. *Gastroenterology* 2001;121(4):767-74.

B.223- Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. *New York State Journal of Medicine* 1988;88:525-527.

B.224- Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. *Int J Geriatr Psychiatry* 1997; 12(9): 913-9.

B.225- von Sydow K, Lieb R, Pfister H, Hofler M, Sonntag H, Wittchen HU. The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. *Drug Alcohol Depend* 2001;64(3):347-61.

B.226- Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. *Ann Intern Med* 1997;126(10):791-8.

*B.227- Wachtel SR, ElSohly MA, Ross SA, Ambre J, De Wit H. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl)* 2002;161(4):331-9 (same as C.150-).

B.228- Wagner JA, Jarai Z, Batkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. *Eur J Pharmacol* 2001; 423(2-3): 203-10.

B.229- Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. *Proc Natl Acad Sci U S A* 1999; 96(21): 12198-203.

B.230- Warms CA, Turner JA, Marshall HM, Cardenas DD. Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful. *Clin J Pain* 2002;18(3):154-63.

B.231- Watson M. Does marijuana use cause long-term cognitive deficits? *JAMA* 2002;287(20):2652.

B.232- Williams CM, Kirkham TC. Observational analysis of feeding induced by Delta(9)-THC and anandamide. *Physiol Behav* 2002;76(2):241-50.

B.233- Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. *Thorax* 1976; 31(6): 720-3.

B.234- Williamson EM, Evans FJ. Cannabinoids in clinical practice. *Drugs* 2000;60(6):1303-14.

B.235- Wish ED. Preemployment drug screening. *JAMA* 1990;264(20):2676-2677.

B.236- Wright A, Terry P. Modulation of the effects of alcohol on driving-related psychomotor skills by chronic exposure to cannabis. *Psychopharmacology (Berl)* 2002;160(2):213-9.

B.237- Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, Watanabe S, Yamamoto T. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. *Brain Res* 2001;909(1- 2):121-6.

B.238- Zwerling C, Ryan J, Orav EJ. The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. *JAMA* 1990;264(20):2639-2643.

C- Materials referenced by DHHS in "Basis for the Recommendation for Maintaining Marijuana in Schedule I of the Controlled Substances Act"

*C.1- Abrams, D.I., Hilton, J.F., Leiser, R.J., Shade, S.B., Elbeik, T.A., Aweeka, F.T., Benowitz, N.L., Bredt, B.M., Kosel, B., Aberg, J.A., Deeks, S.G., Mitchell, T.F., Mulligan, K., Bacchetti, P., McCune, J.M., and Schambelan, M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Ann Intern Med.* 2003 Aug 19; 139(4): 258-66 (same as D.1-).

*C.2- Adams, I.B. and Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. *Addiction.* 1996; 91(11): 1585-1614 (same as D.2-).

*C.3- Agurell, S., Dewey, W.L., and Willett, R.E., eds. *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects.* New York: Academic Press. 1984 (same as D.3-).

*C.4- Agurell, S., Halldin, M., Lindgren, J.E., Ohlsson, A., Widman, M., Gillespie, H., and Hollister, L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev.* 1986; 38(1): 21-43 (same as D.4-).

C.5- Almiraz, R.G., Smith, C.G., and Asch, R.H. The effects of marijuana extract and delta 9-tetrahydrocannabinol on luteal function in the rhesus monkey. *Fertil Steril.* 1983 Feb; 39(2): 212-7.

*C.6- Ameri, A. The effects of cannabinoids on the brain. *Progress in Neurobiology.* 1999; 58(4): 315-348 (same as D.6-).

C.7- American Academy of Pain Medicine, American Pain Society and American Society of Addiction Medicine Consensus Document. Definitions related to the use of opioids for the treatment of pain. 2001.

*C.8- Andreasson, S., Allebeck, .P, Engstrom, A., and Rydberg, U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet.* 1987 Dec 26; 2(8574): 1483-6 (same as D.7-).

C.9- Asch, R.H., Smith, C.G., Siler-Khodr, T.M., and Pauerstein, C.J. Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (*Macaca mulatta*). *J Clin Endocrinol Metab.* 1981 Jan; 52(1): 50-5.

C.10- Balster, R.L. and Prescott, W.R., delta9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. *Neurosci. & Biobehav. Rev.* 1992; 16(1): 55-62.

C.11- Balster, R.L. and Bigelow, G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. *Drug and Alcohol Dependence.* 2003; 70: S13-S40.

C.12- Barnett, G., Licko, V., and Thompson, T. Behavioral pharmacokinetics of marijuana. *Psychopharmacology*. 1985: 85(1): 51-56.

*C.13- Benowitz, N.L. and Jones, R.T. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. *Clin Pharmacol Ther*. 1975 Sep; 18(3): 287-97 (same as D.14-).

*C.14- Benowitz, N.L. and Jones, R.T. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol*. 1981 Aug-Sep; 21(8-9 Suppl): 214S-223S (same as D.15-).

*C.15- Block, R.I. and Wittenborn, J.R. Marijuana effects on associative processes. *Psychopharmacology (Berl)*. 1985; 85(4): 426-30 (same as D.16-).

*C.16- Block, R.I., Farinpour, R., and Schlechte, J.A. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. *Drug Alcohol Depend*. 1991 Aug; 28(2): 121-8 (same as D.18-).

*C.17- Block, R.I., Farinpour, R., and Braverman, K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. *Pharmacol Biochem Behav*. 1992 Nov; 43(3): 907-17 (same as D.17-).

*C.18- Bolla, K.I., Brown, K., Eldreth, D., Tate, K., and Cadet, J.L. Dose-related neurocognitive effects of marijuana use. *Neurology*. 2002; 59: 1337-1343 (same as D.19-).

*C.19- Bolla, K.I., Eldreth, D.A., Matochik, J.A., and Cadet, J.L. Neural substrates of faulty decision-making in abstinent marijuana users. *NeuroImage*. 2005; 26: 480-492 (same as D.20-).

*C.20- Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G., and Casellas, P. Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem*. 1993 May 15; 214(1): 173-80 (same as D.21).

*C.21- Braidá, D., Iosue, S., Pegorini, S., and Sala, M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. *Eur J Pharmacol*. 2004 Dec 3; 506(1): 63-9 (same as D.22).

*C.22- Breivogel, C.S. and Childers, S.R. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther*. 2000 Oct; 295(1): 328-36 (same as D.23-).

*C.23- Breivogel et al., 2001 (same as B.18-).

*C.24- Breivogel, C.S., Scates, S.M., Beletskaya, I.O., Lowery, O.B., Aceto, M.D., and Martin, B.R. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. *Eur J Pharmacol*. 2003 Jan 17; 459(2-3): 139-50 (same as D.24-).

C.25- Brown, T.T. and Dobs, A.S. Endocrine effects of marijuana. *J Clin Pharmacol.* 2002 Nov: 42(11 Suppl): 90S-96S.

*C.26- Browne, R.G. and Weissman, A. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. *J Clin Pharmacol.* 1981 Aug-Sep: 21(8-9 Suppl): 227S-234S (same as D.25-).

*C.27- Budney, A.J., Novy, P.L., and Hughes, J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. *Addiction.* 1999: 94(9): 1311-22 (same as D.27-).

*C.28- Budney, A.J., Hughes, J.R., Moore, B.A., and Vandrey, R. Review of the validity and significance of cannabis withdrawal syndrome. *Am J Psychiatry.* 2004 Nov: 161(11): 1967-77 (same as D.26-).

C.29- Cadoni, C., Pisanu, A., Solinas, M., Acquas, E., and Di Chiara, G. Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. *Psychopharmacology (Berl).* 2001 Nov: 158(3): 259-66.

*C.30- Capriotti, R.M., Foltin, R.W., Brady, J.V., and Fischman, M.W. Effects of marijuana on the task-elicited physiological response. *Drug Alcohol Depend.* 1988 Jul: 21(3): 183-7 (same as D.30-).

C.31- Chait, L.D., Fischman, M.W., and Schuster, C.R. 'Hangover' effects the morning after marijuana smoking. *Drug Alcohol Depend.* 1985 Jun:15(3): 229-38.

*C.32- Chait, L.D., Evans, S.M., Grant, K.A., Kamien, J.B., Johanson, C.E., and Schuster, C.R. Discriminative stimulus and subjective effects of smoked marijuana in humans. *Psychopharmacology (Berl).* 1988: 94(2): 206-12 (same as D.36).

*C.33- Chait, L.D. and Burke, K.A. Preference for high- versus low-potency marijuana. *Pharmacol Biochem Behav.* 1994 Nov: 49(3): 643-7 (same as D.33-).

C.34- Chaperon, F., Soubrie, P., Puech, A.J., and Thiebot, M.H. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. *Psychopharmacology (Berl).* 1998 Feb: 135(4): 324-32.

C.35- Cheer, J.F., Kendall, D.A., and Marsden, C.A. Cannabinoid receptors and reward in the rat: a conditioned place preference study. *Psychopharmacology (Berl).* 2000 Jul:151(1): 25-30.

C.36- Community Epidemiology Work Group, National Institutes of Health, National Institute on Drug Abuse, *Epidemiologic Trends in Drug Abuse, Volume I: Highlights and Executive Summary*, June 2000, <http://www.nida.nih.gov/CEWG/pubs.html>.

*C.37- Cone, E.J., Johnson, R.E., Moore, J.D., and Roache, J.D. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. *Pharmacol Biochem Behav.* 1986 Jun; 24(6): 1749-54 (same as D.40-).

*C.38- Croxford, J.L. and Yamamura, T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? *J Neuroimmunol.* 2005 Sep; 166(1-2): 3-18. Review (same as D.43).

*C.39- Dax, E.M., Pilotte, N.S., Adler, W.H., Nagel, J.E., and Lange, W.R. The effects of 9-ene-tetrahydrocannabinol on hormone release and immune function. *J Steroid Biochem.* 1989; 34(1-6): 263-70 (same as D.44).

*C.40- Degenhardt, L., Hall, W., and Lynskey, M. Testing hypotheses about the relationship between cannabis use and psychosis. *Drug Alcohol Depend.* 2003 Jul 20; 71(1): 37-48 (same as D.45).

*C.41- Department of Health and Human Services. Announcement of the Department of Health and Human Services Guidance on Procedures for the Provision of Marijuana for Medical Research. May 21, 1999. (<http://grants.nih.gov/grants/guide/notice-files/not99-091.html>) (same as D.47-).

*C.42- Dewey, W. L., Martin, B. R., and May, E. L. Cannabinoid stereoisomers: pharmacological effects. In Smith, D. F. (Ed.) *CRC Handbook of stereoisomers: drugs in psychopharmacology*, 317-326 (Boca Raton, FL, CRC Press), 1984 (same as D.48-).

C.43- D'Souza, D.C., Abi-Saab, W.M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T.B., and Krystal, J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. *Biol Psychiatry.* 2005 Mar 15; 57(6): 594-608.

C.44- Drug Enforcement Administration, Federal-wide Drug Seizure System, 1989–2002 (October 2002).

C.45- Drug Enforcement Administration, *Drugs of Abuse*, 2005.

C.46- Drug Enforcement Administration. *Sourcebook of Criminal Justice Statistics*, 2003. Excerpt

C.47- DSM-IV-TR: *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision*. American Psychiatric Association. Arlington, VA: American Psychiatric Publishing, Inc., 2000.

*C.48- Ehrenreich, H., Rinn, T., Kunert, H.J., Moeller, M.R., Poser, W., Schilling, L., Gigerenzer, G., and Hoehle, M.R. Specific attentional dysfunction in adults following early start of cannabis use. *Psychopharmacology (Berl).* 1999 Mar; 142(3): 295-301 (same as D.49).

C.49- Eldreth, D.A., Matochik, J.A., Cadet, J.L., and Bolla, K.I. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. *Neuroimage*. 2004 Nov: 23(3): 914-20.

*C.50- Eldridge, J.C., Murphy, L.L., and Landfield, P.W. Cannabinoids and the hippocampal glucocorticoid receptor: recent findings and possible significance. *Steroids*. 1991 May: 56(5): 226-31. Review (same as D.50).

*C.51- Fant, R.V., Heishman, S.J., Bunker, E.B., and Pickworth, W.B. Acute and residual effects of marijuana in humans. *Pharmacol Biochem Behav*. 1998 Aug: 60(4): 777-84 (same as D.51).

C.52- Favrat, B., Menetrey, A., Augsburger, M., Rothuizen, L.E., Appenzeller, M., Buclin, T., Pin, M., Mangin, P., and Giroud, C. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. *BMC Psychiatry*. 2005 Apr 1: 5(1): 17.

*C.53- Fergusson, D.M., Horwood, L.J., and Ridder, E.M. Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction*. 2005 Mar: 100(3): 354-66 (same as D.53-).

C.54- Note about Fried (1987). This citation contains the title of a later article, and the journal and numerical reference of an earlier article by the same authors. Both articles are included herein.

C.55- Fried, P.A. Watkinson, B, and Dillon, R.F. Neonatal neurological status in a low-risk population after prenatal exposure to cigarettes, marijuana, and alcohol. *Dev. Behav. Pediatr*. 1987: 8: 318- 326.

*C.56- Fried, P.A, and Watkinson, B. 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *Dev. Behav. Pediatr*. 1990: 11: 49-58 (same as D.57).

*C.57- Fried, P.A., Watkinson, B., and Gray, R.A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marihuana, cigarettes and alcohol. *Neurotoxicol. Teratol*. 1992: 14: 299-311 (same as D.58).

*C.58- Fried, P.A., Watkinson, B., and Gray, R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. *Neurotoxicol. Teratol*. 1998: 20(3): 293-306 (same as D.59).

*C.59- Fried et al., 2002 (same as B.63-).

C.60- Fung, M., Gallagher, C., and Machtay, M. Lung and aero-digestive cancers in young marijuana smokers. *Tumori*. 1999: 85 (2): 140-142.

*C.61- Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., and Casellas, P. Expression of central and peripheral

cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem.* 1995 Aug 15: 232(1): 54-61 (same as D.61).

C.62- Gaoni, Y. and Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. *J. Am. Chem. Soc.* 1964: 86: 1646-1647.

*C.63- Gerard, C. M., Mollereau, C., Vassart, G., and Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. *Biochem J.* 1991: 279: 129-34 (same as D.62).

C.64- Ghozland, S., Matthes, H.W., Simonin, F., Filliol, D., Kieffer, B.L., and Maldonado, R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J Neurosci.* 2002 Feb 1: 22(3): 1146-54.

*C.65- Gold, L.H., Balster, R.L., Barrett, R.L., Britt, D.T., and Martin, B.R. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. *J Pharmacol Exp Ther.* 1992 Aug: 262(2): 479-86 (same as D.64).

*C.66- Golub and Johnson, 2001 (same as B.72-).

*C.67- Gong, H. Jr., Tashkin, D.P., Simmons, M.S., Calvarese, B., and Shapiro, B.J. Acute and subacute bronchial effects of oral cannabinoids. *Clin Pharmacol Ther.* 1984 Jan: 35(1): 26-32 (same as D.65).

*C.68- Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro, P.A., Brusco, A., and Uhl, G.R. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. *Brain Res.* 2006 Feb 3: 1071(1): 10-23 (same as D.66).

*C.69- Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D., and Hipkin, R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. *Mol Pharmacol.* 2000 May: 57(5): 1045-50 (same as D.67).

*C.70- Graham, J.D.P., ed. *Cannabis and Health.* New York: Academic Press, 1976 (same as D.68).

C.71- Grant I. Foreword by Igor Grant, M.D., Director, Center for Medicinal Cannabis Research (CMCR). *Neuropharmacology.* 2005 Jun: 48(8): 1067.

*C.72- Griffith, D. R., Azuma, S. D., and Chasnoff, I. J. Three-year outcome of children exposed prenatally to drugs. *J. Am. Acad. Child Adolesc. Psychiatry.* 1994: 33: 20-27(same as D.70).

*C.73- Grotenhermen et al., 2003 (same as B.81-).

C.74- Gruber, A.J., Pope, H.G., Hudson, J.I., and Yurgelun-Todd, D. Attributes of long-term heavy cannabis users: a case-control study. *Psychological Medicine*. 2003; 33: 1415-1422.

C.75- Gruber, S.A. and Yurgelun-Todd, D.A. Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. *Brain Res Cogn Brain Res*. 2005 Apr; 23(1): 107-18.

C.76- Hall, W., Degenhardt, L., and Teesson, M. Cannabis use and psychotic disorders: an update. *Drug Alcohol Rev*. 2004 Dec; 23(4): 433-43.

C.77- Hall, W.D. and Lynskey, M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. *Drug Alcohol Rev*. 2005 Jan; 24(1): 39-48.

*C.78- Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W., and Fischman, M.W. Abstinence symptoms following smoked marijuana in humans. *Psychopharmacology (Berl)*. 1999; 141(4): 395-404 (same as D.73).

C.79- Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R.G., Roos, R. A., Mechoulam, R., and Frider, E. HU-308: a specific agonist for CB (2), a peripheral Cannabinoid receptor. *Proc. Natl. Acad. Sci. USA*. 1999; 96: 14228-33.

C. 80- Pope, H.G. Jr., Gruber, A.J., Hudson, J.I., Huestis, M.A., and Yurgelun-Todd, D. Cognitive measures in long-term cannabis users. *J Clin Pharmacol*. 2002 Nov; 42(11 Suppl): 41S-47S. Review.

*C.81- Heishman, S.J., Huestis, M.A., Henningfield, J.E., and Cone, E.J. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol Biochem Behav*. 1990 Nov; 37(3): 561-5 (same as D.78).

*C.82- Herkenham, M. Cannabinoid receptor localization in brain: Relationship to motor and reward systems. In: Kalivas, P.W., and Samson, H.H., eds. *The neurobiology of drug and alcohol addiction*. *Ann N Y Acad Sci* 1992; 654: 19-32 (same as D.82).

*C.83- Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. Cannabinoid receptor localization in Brain. *Proc. Natl. Acad. Sci. U S A*. 1990; 87: 1932-1936 (same as D.83).

C.84- Herning, R.I., Hooker, W.D., and Jones, R.T. Tetrahydrocannabinol content and differences in marijuana smoking behavior. *Psychopharmacology*. 1986; 90(2): 160-162.

C.85- Hively, R. L., Mosher, W. A., and Hoffman, F. W. Isolation of trans-delta6-tetrahydrocannabinol from marihuana. *J. Am. Chem. Soc*. 1966; 88: 1832-1833.

*C.86- Hollister, L.E. Health aspects of cannabis. *Pharmacological Rev*. 1986; 38: 1-20 (same as D.84).

*C.87- Hollister, L.E. Cannabis. (Literature review). Acta Psychiatr Scand (Suppl). 1988: 78: 108-118 (same as D.85).

*C.88- Howlett, A.C., Breivogel, C.S., Childers, S.R., Deadwyler, S.A., Hampson, R.E., and Porrino, L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004: 47 Suppl 1: 345-58 (same as D.86).

C.89- Huestis, M. A., Sampson, A. H., Holicky, B. J., Henningfield, J. E., and Cone, E. J. Characterization of the absorption phase of marijuana smoking. Clin. Pharmacol. Ther. 1992a: 52: 31-41.

C.90- Huestis, M.A., Henningfield, J.E.; and Cone, E.J. Blood Cannabinoids. 1. Absorption of THC and formation of 11-OH-THC and THC COOH during and after smoking marijuana. J Anal Toxicol. 1992b: 16(5): 276-282.

C.91- Hunt, C.A. and Jones, R.T. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther. 1980 Oct: 215(1): 35-44.

C.92- Institute of Medicine. Division of Health Sciences Policy. Marijuana and Health: Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.

*C.93- Joy et al., 1999 (same as B.112-).

C.94- Johansson, E., Halldin, M.M., Agurell, S., Hollister, L.E.; and Gillespie, H.K. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989: 37(3): 273-277.

C.95- Johnston, L. D., O'Malley, P. M., Bachman, J. G., and Schulenberg, J. E. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2005 (NIH Publication No. 06-5882). Bethesda, MD: National Institute on Drug Abuse, 2006: 67.

C.96- Jones, R.T., Benowitz, N.L., and Herning, R.I. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol. 1981: 21: 143S-152S.

*C.97- Jones, R.T. Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002 Nov: 42(11 Suppl): 58S-63S (same as D.92-).

*C.98- Justinova, Z., Tanda, G., Redhi, G.H., and Goldberg, S.R. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 2003 Sep: 169(2): 135-40 (same as D.96-).

*C.99- Kandel, D.B. and Chen, K. Types of marijuana users by longitudinal course. J Stud Alcohol. 2000 May: 61(3): 367-78 (same as D.99-).

*C.100- Kirk, J.M. and de Wit, H. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. *Pharmacol Biochem Behav.* 1999 May: 63(1): 137-42 (same as D.102).

*C.101- Kurzthaler, I., Hummer, M., Miller, C., Sperner-Unterweger, B., Gunther, V., Wechdorn, H., Battista, H.J., and Fleischhacker, W.W. Effect of cannabis use on cognitive functions and driving ability. *J Clin Psychiatry.* 1999 Jun: 60(6): 395-9 (same as D.105-).

*C.102- Lane, J.D. and Phillips-Bute, B.G. Caffeine deprivation affects vigilance performance and mood. *Physiol Behav.* 1998: 65: 171-5 (same as D.106-).

C.103- Lemberger, L., Silberstein, S. D., Axelrod, J., and Kopin, I. J. Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. *Science.* 1970: 170: 1320-1322.

C.104- Lemberger, L., Weiss, J. L., Watanabe, A. M., Galanter, I. M., Wyatt, R. J., and Cardon, P. V. Delta-9-tetrahydrocannabinol: temporal correlation of the psychological effects and blood levels after various routes of administration. *New Eng. J. Med.* 1972a: 286(13): 685-688.

*C.105- Lemberger, L., Crabtree, R. E., and Rowe, H. M. 11 Hydroxy-9-tetrahydrocannabinol: pharmacology, disposition and metabolism of a major metabolite of marihuana in man. *Science.* 1972b: 177: 62-64 (same as D.107-).

C.106- Lemberger, L. and Rubin, A. The physiologic disposition of marihuana in man. *Life Sci.* 1975: 17: 1637-42.

*C.107- Liguori, A., Gatto, C.P., and Robinson, J.H. Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. *Behav Pharmacol.* 1998 Nov: 9(7): 599-609 (same as D.108-).

*C.108- Lyketsos et al., 1999 (same as B.125-).

*C.109- Lyons, M.J., Bar, J.L., Panizzon, M.S., Toomey, R., Eisen, S., Xian, H., and Tsuang, M.T. Neuropsychological consequences of regular marijuana use: a twin study. *Psychol Med.* 2004 Oct: 34(7): 1239-50 (same as D.111-).

*C.110- Mackie, K., Lai, Y., Westenbroek, R., and Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci.* 1995 Oct: 15(10): 6552-61 (same as D.112-).

*C.111- Maldonado, R. Study of cannabinoid dependence in animals. *Pharmacol Ther.* 2002 Aug: 95(2): 153-64 (same as D.113-).

- C.112- Maremmani, I., Lazzeri, A., Pacini, M., Lovrecic, M., Placidi, G.F., and Perugi, G. Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. *J Psychoactive Drugs*. 2004 Jun: 36(2): 235-41.
- *C.113- Martellotta, M.C., Cossu, G., Fattore, L., Gessa, G.L., and Fratta, W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. *Neuroscience*. 1998 Jul: 85(2): 327-30 (same as D.116-).
- *C.114- Mathers, D.C. and Ghodse, A.H. Cannabis and psychotic illness. *Br J Psychiatry*. 1992 Nov: 161: 648-53 (same as D.119-).
- *C.115- Martin, B.R., Mechoulam, R., and Razdan, R.K. Discovery and characterization of endogenous cannabinoids. *Life Sci*. 1999: 65: 573-595 (same as D.118-).
- * C.116- Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature*. 1990: 346: 561-564 (same as D.121-).
- C.117- Mechoulam, R. Cannabinoid chemistry. In Mechoulam, R. (ED.) *Marijuana* (New York, NY, Academic Press, Inc.), 1973: 12-88.
- C.118- Mendelson, J.H. and Mello, N.K. Effects of marijuana on neuroendocrine hormones in human males and females. *NIDA Res Monogr*. 1984: 44: 97-114.
- *C.119- Messinis, L., Kyprianidou, A., Malefaki, S., and Papathanasopoulos, P. Neuropsychological deficits in long-term frequent cannabis users. *Neurology*. 2006: 66: 737-739 (same as D. 131-).
- C.120- Monitoring the Future. National Results on Adolescent Drug Use. Overview of 1999 Key findings, 1999. Department of Health and Human Services. National Institute on Drug Abuse. Rockville, MD. (<http://monitoringthefuture.org>)
- C.121- Nace, E.P., Meyers, A.L., Rothberg, J.M., and Maleson, F. Addicted and nonaddicted drug users. A comparison of drug usage patterns. *Arch Gen Psychiatry*. 1975: 32(1): 77-80.
- C.122- National Institutes of Health (NIH). Workshop on the medical Utility of Marijuana, February 19-20, 1997. (www.nih.gov/news/medmarijuana/MedicalMarijuana.htm)
- C.123- Office of National Drug Control Policy. The National Drug Control Strategy: 2000 Annual Report. Superintendent of Documents, Mail Stop: SSOP, Washington, DC.
- C.124- Oviedo, A., Glowa, J. and Herkenham, M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. *Brain Res*. 1993: 616: 293-302.

- C.125- Pencer, A., Addington, J., and Addington, D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. *Psychiatry Res.* 2005 Jan 30: 133(1): 35-43.
- *C.126- Piomelli, D. The endocannabinoid system: a drug discovery perspective. *Curr Opin Investig Drugs.* 2005 Jul: 6(7): 672-9 (same as D.139-).
- *C.127- Pope, H.G. Jr., Gruber, A.J., Hudson, J.I., Cohane, G., Huestis, M.A., and Yurgelun-Todd, D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? *Drug Alcohol Depend.* 2003 Apr 1: 69(3): 303-10 (same as D.141-).
- *C.128- Ramaekers, J.G., Berghaus, G., van Laar, M., and Drummer, O.H. Dose related risk of motor vehicle crashes after cannabis use. *Drug Alcohol Depend.* 2004 Feb 7: 73(2): 109-19 (same as D.142-).
- *C.129- Rodriguez de Fonseca, F., Gorriti, M.A., Fernandez-Ruiz, J.J., Palomo, T., and Ramos, J.A. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol. Biochem. Behav.* 1994: 47 (1): 33-40 (same as D.145-).
- *C.130- Ross, S. A. and El Sohly, M. A. Constituents of Cannabis Sativa L. A review of the natural constituents: 1980-1994. *Zagazig J. Pharm. Sci.* 1995: 4 (2): 1-10 (same as D.146-).
- *C.131- Roth, M.D., Tashkin, D.P., Whittaker, K.M., Choi, R., and Baldwin, G.C. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. *Life Sci.* 2005 Aug 19: 77(14): 1711-22 (same as D.147-).
- *C.132- Sanudo-Pena, M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., and Walker, J. M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. *Neurosci. Lett.* 1997: 223: 125-128 (same as D.148-).
- C.133- Sarfaraz, S., Afaq, F., Adhami, V.M., and Mukhtar, H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. *Cancer Res.* 2005 Mar 1: 65(5): 1635-41.
- *C.134- Schiffman, J., Nakamura, B., Earleywine, M., and LaBrie, J. Symptoms of schizotypy precede cannabis use. *Psychiatry Res.* 2005 Mar 30: 134(1): 37-42 (same as D.149-).
- *C.135- Sidney, S. Cardiovascular consequences of marijuana use. *J Clin Pharmacol.* 2002 Nov: 42(11 Suppl): 64S-70S (same as D.151-).
- *C.136- Solowij, N., Stephens, R.S., Roffman, R.A., Babor, T., Kadden, R., Miller, M., Christiansen, K., McRee, B., and Vendetti, J. Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. *JAMA.* 2002 Mar 6: 287(9): 1123-31 (same as D.153-).

C.137- Stirling, J., Lewis, S., Hopkins, R., and White, C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. *Schizophr Res.* 2005 Jun 1; 75(1): 135-7.

C.138- Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-28, HHS Publication No. (SMA) 06-4143, Rockville, MD, 2006.

C.139- Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-28, HHS Publication No. SMA 05-4062). Rockville, MD, 2005.

C.140- Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights - 2004. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-31, HHS Publication No. (SMA) 06-4140, Rockville, MD, 2006.

*C.141- Tanda et al., 2000 (same as B.214-).

C.142- Tashkin, D.P. Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis.* 2005 Jun; 63(2): 93-100.

*C.143- Tashkin, D.P., Zhang, Z.F., Greenland, S., Cozen, W., Mack, T.M., and Morgenstern, H. Marijuana Use and Lung Cancer: Results of a Case-Control Study. Abstract #A777, American Thoracic Society meeting, May 24, 2006 (same as D.157-).

*C.144- Thornicroft, G. Cannabis and psychosis. Is there epidemiological evidence for an association? *Br J Psychiatry.* 1990 Jul; 157: 25-33 (same as D.160-).

*C.145- Twitchell, W., Brown, S., and Mackie, K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. *J Neurophysiol.* 1997 Jul; 78(1): 43-50 (same as D.162-).

C.146- Tzilos, G.K., Cintron, C.B., Wood, J.B., Simpson, N.S., Young, A.D., Pope, H.G. Jr., and Yurgelun-Todd, D.A. Lack of hippocampal volume change in long-term heavy cannabis users. *Am J Addict.* 2005 Jan-Feb; 14(1): 64-72.

*C.147- Vandrey, R.G., Budney, A.J., Moore, B.A., and Hughes, J.R. A cross-study comparison of cannabis and tobacco withdrawal. *Am J Addict.* 2005 Jan-Feb; 14(1): 54-63 (same as D.165-).

*C.148- van Os, J., Bak, M., Hanssen, M., Bijl, R.V., de Graaf, R., and Verdoux, H. Cannabis use and psychosis: a longitudinal population-based study. *Am J Epidemiol.* 2002 Aug 15; 156(4): 319-27 (same as D.164-).

C.149- von Sydow, K., Lieb, R., Pfister, H., Hofler, M., and Wittchen, H.U. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. *Drug Alcohol Depend.* 2002 Sep 1; 68(1): 49-64.

*C.150- Wachtel et al., 2002 (same as B.227-).

*C.151- Wagner, J.A., Varga, K., and Kunos, G. Cardiovascular actions of cannabinoids and their generation during shock. *J Mol Med.* 1998 Nov-Dec: 76(12): 824-36(same as D.166-).

C.152- Wiley, J.L., Barrett, R.L., Britt, D.T., Balster, R.L., and Martin, B.R. Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys. *Neuropharmacology.* 1993 Apr: 32(4): 359-65.

*C.153- Wiley, J.L., Huffman, J.W., Balster, R.L., and Martin, B.R. Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. *Drug Alcohol Depend.* 1995 Nov: 40(1): 81-6 (same as D.168-).

C.154- Wu, X. and French, E.D. Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. *Neuropharmacology.* 2000 Jan 28: 39(3): 391-8.

*C.155- Yanagita, T. Self-administration studies on psychological dependence. *Trends in Pharmacological Sciences.* 1979-1980: 1:1: 161-164 (same as D.169-).

*C.156- Zhang, Z.F., Morgenstern, H., Spitz, M.R., Tashkin, D.P., Yu, G.P., Marshall, J.R., Hsu, T.C., and Schantz, S.P. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiol Biomarkers Prev.* 1999 Dec: 8(12): 1071-8 (same as D.170-).

D. Materials referenced by DEA in Marijuana - Scheduling Review Document: Eight Factor Analysis

*D.1- Abrams et al., 2003 (same as C.1-).

*D.2- Adams and Martin, 1996 (same as C.2-).

*D.3- Agurell et al., 1984 (same as C.3-).

*D.4- Agurell et al., 1984. (same as C.4-).

D.5- Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, Pritchard A, Robinson G, Beasley R; Cannabis and Respiratory Disease Research Group (2008). Cannabis use and risk of lung cancer: a case-control study. *European Respiratory Journal.* 31(2):280-6.

*D.6- Ameri, 1999 (same as C.6-).

*D.7- Andreasson et al., 1987 (same as C.8-).

D.8- Arseneault, L., Cannon, M., Poulton, R., Murray R., Caspi, A., and Moffitt, T.E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. *British Medical Journal*. 325 (7374):1212–1213.

D.9- Azorlosa, J., Heishman, S., Stitzer, M., and Mahaffey, J.M. (1992). Marijuana smoking: effect of varying delta-9- tetrahydrocannabinol content and number of puffs. *Journal of Pharmacology and Experimental Therapeutics*. 261:114–122.

D.10- Baldwin, G.C., Tashkin, D.P., Buckley, D.M., Park, A.N., Dubinett, S.M., and Roth, M.D. (1997). Marijuana and cocaine impair alveolar macrophage function and cytokine production. *American Journal of Respiratory and Critical Care Medicine*. 156:1606–1613.

D.11- Balster, R.L. and Prescott, W.R. (1992). D9- tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. *Neuroscience and Biobehavioral Reviews*. 16: 55–62.

D.12- Barrett, R.L., Wiley, J.L., Balster, R.L. and Martin, B.R. (1995). Pharmacological specificity of D9-tetrahydrocannabinol discrimination in rats. *Psychopharmacology*. 118: 419–424.

D.13- Bedard, M., Dubois, S., Weaver, B. (2007). The impact of cannabis on driving. *Canadian Journal of Public Health*. 98(1):6–11.

*D.14- Benowitz and Jones, 1975 (same as C.13-).

*D.15- Benowitz and Jones, 1981 (same as C.14-).

*D.16- Block and Wittenborn, 1985 (same as C.15-).

*D.17- Block et al., 1992 (same as C.17-).

*D.18- Block et al., 1991 (same as C.16-).

*D.19- Bolla et al., 2002 (same as C.18-).

*D.20- Bolla et al., 2005 (same as C.19-).

*D.21- Bouaboula et al., 1993 (same as C.20-).

*D.22- Braida et al., 2004 (same as C.21-).

*D.23- Breivogel et al., 2000 (same as C.22-).

*D.24- Breivogel et al., 2003 (same as C.24-).

*D.25- Browne et al., 1981 (same as C.26-).

*D.26- Budney et al., 2004 (same as C.28-).

*D.27- Budney et al., 1999 (same as C.27-).

D.28- Cabral, G.A. and Dove-Pettit, D.A. (1998). Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. *Journal of Neuroimmunology*. 83(1–2):116–123.

D.29- Cabral, G.A. and Staab, A. (2005). Effects on the immune system. *Handbook of Experimental Pharmacology*. 168:385–423.

*D.30- Capriotti et al., 1988 (same as C.30-).

D.31- Caspi, A., Moffitt, T.E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., Poulton, R., and Craig, I.W. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. *Biological Psychiatry*. 57(10):1117–1127.

D.32- Centers for Disease Control (CDC). (1981). Salmonellosis traced to marijuana— Ohio, Michigan. *Morbidity and Mortality Weekly Report*. 30(7):77–9.

*D.33- Chait and Burke, 1994 (same as C.33-).

D.34- Chait, L.D. and Pierri, J. (1992). Effects of smoked marijuana on human performance. *In: Marijuana/Cannabinoids. Neurobiology and Neurophysiology*. Murphy, L., and Bartke, A. (Eds). CRC Press, Boca Raton, FL. Pp. 387–423.

D.35- Chait, L.D. and Zacny, J.P. (1992). Reinforcing and subjective effects of oral D9-THC and smoked marijuana in humans. *Psychopharmacology*. 107:255–262.

*D.36- Chait et al., 1988 (same as C.32-).

D.37- Charuvastra, A., Friedmann, P.D., Stein, M.D. (2005). Physician attitudes regarding the prescription of medical marijuana. *Journal of Addiction Diseases*. 24(3):87–93.

D.38- Cocchetto, D.M., Owens, S.M., Perez-Reyes, M., DiGuseppi, S., and Miller, L.L. (1981). Relationship between delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. *Psychopharmacology*. 75:158–164.

D.39- Collins, R.J., Weeks, J.R., Cooper, M.M., Good, P.I., and Russell, R.R. (1984). Prediction of abuse liability of drugs using IV self-administration by rats. *Psychopharmacology*, 82: 6–13.

*D.40- Cone et al., 1986 (same as C.37-).

D.41- Cone, E.J., Johnson, R.E., Paul, B.D., Mell, L.D., and Mitchell, J. (1988). Marijuana laced brownies: Behavioral effects, physiological effects and urinalysis in humans following ingestion. *Journal of Analytical Toxicology*. 12:169–175.

D.42- Crider, R. (1986). Phencyclidine: changing abuse patterns. *NIDA Research Monograph*. 64:163–173.

*D.43- Croxford et al., 2005 (same as C.38-).

*D.44- Dax et al., 1989 (same as C.39-).

*D.45- Degenhardt et al., 2003 (same as C.40-).

D.46- Note about Department of Health and Human Services (2006). Basis For The Recommendation For Maintaining Marijuana In Schedule I Of The Controlled Substances Act. A copy of this document is located in the Correspondence folder, under tab number 10.

*D.47- Department of Health and Human Services, 1999 (same as C.41-).

*D.48- Dewey et al., 1984 (same as C.42-).

*D.49- Ehrenreich et al., 1999 (same as C.48-).

*D.50- Eldridge et al., 1991 (same as C.50-).

*D.51- Fant et al., 1998 (same as C.51-).

D.52- Felder, C.C., Joyce, K.E., Briley, E.M., Glass, M., Mackie, K.P., Fahey, K.J., Cullinan, G.J., Hunden, D.C., Johnson, D.W., Chaney, M.O., Koppel, G.A. and Brownstein, M. (1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasking coupling of the CB1 receptor to stimulation of cAMP accumulation. *Journal of Pharmacology and Experimental Therapeutics*. 284: 291– 297

*D.53- Fergusson et al., 2005 (same as C.53-).

D.54 Fergusson, D.M., Poulton, R., Smith, P.F., Boden, J.M. (2006). Cannabis and psychosis. *British Medical Journal*. 332(7534):172–5.

D.55- Fligel, S.E., Roth, M.D., Kleerup, E.C., Barsky, S.H., Simmons, M., and Tashkin, D.P. (1997). Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. *Chest*. 112:319–326.

D.56- Foltin, R.W., Fischman M.W., Brady J.V., Bernstein D.J., Capriotti, R.M., Nellis, M.J., and Kelly, T.H. (1990). Motivational effects of smoked marijuana: behavioral contingencies and low probability activities. *Journal of the Experiment Analysis of Behavior*. 53:5–19.

*D.57- Fried, and Watkinson, 1990 (same as C.56-).

*D.58- Fried et al., 1992 (same as C.57-).

*D.59- Fried et al., 1998 (same as C.58-).

*D.60- Fung et al., 1999 (same as C.60-).

*D.61- Galiegue et al., 1995 (same as C.61-).

*D.62- Gerard et al., 1991 (same as C.63-).

D.63- Glass, M. and Felder, C.C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. *Journal of Neuroscience*. 17: 5327–5333.

*D.64- Gold et al., 1992 (same as C.65-).

*D.65- Gong et al., 1984 (same as C.67-).

*D.66- Gong et al., 2006 (same as C.68-).

*D.67- Gonsiorek et al., 2000 (same as C.69-).

*D.68- Graham, 1976 (same as C.70-).

D.69- Green B., Young, R., and Kavanagh, D. (2005). Cannabis use and misuse prevalence among people with psychosis. *British Journal of Psychiatry*. 187:306–313.

*D.70- Griffith et al., 1994 (same as C.72-).

D.71- Griffiths, R.R., Bigelow, G.E. and Henningfield, J.E. (1980). Similarities in animal and human drug-taking behavior. In: “Advances in substance abuse, vol 1”. (Ed. N.K. Mello). pp. 1–90. JAI Press, Greenwich, CT.

D.72- Hall, W., Degenhardt, L., Teesson, M. (2004). Cannabis use and psychotic disorders: an update. *Drug and Alcohol Reviews*. 23(4):433–43.

*D.73- Haney et al., 1999 (same as C.78-).

D.74- Hanus, L. and Subiva, D. (1989). The amount of main cannabinoid substances in hemp cultivated for industrial fibre production and their changes in the course of one vegetation period. *Acta Universitatis Palackianae Olomucensis Facultatis Medicae*. 122:11–23.

D.75- Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R.G., Roos, R.A., Mechoulam, R., and Fride, E. (1999). HU-308: a specific agonist for CB (2), a peripheral Cannabinoid receptor. *Proceedings of the National Academy of Science*. 96:14228–14233.

D.76- Hanus, L., Yoshida, T., and Kreji. (1975). Production of D9-tetrahydrocannabinol from hemp cultivated in climatic conditions of Czechoslovakia. *Acta Universitatis Palackianae Olomucensis Facultatis Medicae*. 74:173–180.

D.77- Harder, S. and Rietbrock, S. (1997). Concentration-effect relationship of delta- 9- tetrahydrocannabinol and prediction of psychotropic effects after smoking marijuana. *International Journal of Clinical Pharmacology and Therapeutics*. 35(4):155–159.

*D.78- Heishman et al., 1990 (same as C.81-).

D.79- Heishman, S.J., Singleton, E.G., and Ligouri, A. (2001). Marijuana craving questionnaire: development and initial validation of a self-report instrument. *Addiction*. 96(7):1023–1034.

D.80- Heishman, S.J., Stitzer, M.L., and Bigelow, G.E. (1988). Alcohol and marijuana: Comparative dose effect profiles in humans. *Pharmacology, Biochemistry and Behavior*. 31:649–655.

D.81- Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H.U., and van Os, J. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. *British Medical Journal*. 330(7481):11.

*D.82- Herkenham , 1992 (same as C.82-).

*D.83- Herkenham et al., 1990 (same as C.83-).

*D.84- Hollister, 1986 (same as C.86-).

*D.85- Hollister, 1988 (same as C.87-).

*D.86- Howlett et al., 2004 (same as C.88-).

D.87- Idanpaan-Heikkila, J., Fritchie, G.E., Englert, L.F., Ho, B.T. and McIsaac, W.M. (1969). Placental transfer of tritiated-1-delta-9- tetrahydrocannabinol. *New England Journal of Medicine*. 281(6):330.

D.88. Note about Institute of Medicine, Division of Neuroscience and Behavioral Health. (1999). This book was also cited by the petitioner, and can be found in the petitioner's administrative record under: Joy JE, Watson SJ, Benson JAY editors. Marijuana and medicine: Assessing the science base. Washington DC: Institute of Medicine, National Academy Press, 1999

D.89- Jarbe, T.U., Lamb, R.J., Lin, S., and Makriyannis, A. (2001). (R)-methandamide and delta-9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. *Psychopharmacology*. 156(4):369-380.

D.90- Johanson, C.E. and Balster, R.L. (1978). A summary of the results of a drug selfadministration study using substitution procedures in rhesus monkeys. *Bulletin of Narcotics*, 30:43-54.

D.91- Jones, R.T. (1980). Human Effects: An Overview. In *NIDA Research Monograph 31, Marijuana Research Findings: 1980*. 31:54-80.

*D.92- Jones, 2002 (same as C.97-).

D.93- Justinova, Z., Goldberg, S.R., Heishman, S.J., Tanda, G. (2005). Self-administration of cannabinoids by experimental animals and human marijuana smokers. *Pharmacology Biochemistry and Behavior*. 81(2):285-99.

D.94- Justinova, Z., Munzar, P., Panlilio, L.V., Yasar, S., Redhi, G.H., Tanda, G., Goldberg, S.R. (2008). Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. *Neuropsychopharmacology*. 33(12):2870-7.

D.95- Justinova, Z., Tanda, G., Munzar, P., Goldberg, S.R. (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology (Berl)*. 173(1-2):186-94.

*D.96- Justinova et al., 2003 (same as C.98-).

D.97- Kagen, S.L., Kurup, V.P., Sohnle, P.G., Fink, J.N. (1983). Marijuana smoking and fungal sensitization. *The Journal of Allergy and Clinical Immunology*. 71(4):389-93.

D.98- Kamien, J.B., Bickel, W.K., Higgins, S.T., and Hughes, J.R. (1994). The effects of D9-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans. *Behavioural Pharmacology*. 5: 71-78.

*D.99- Kandel and Chen, 2000 (same as C.99-).

D.100- Kelly, T.H., Foltin, R.W., and Fischman, M.W. (1993). Effects of smoked marijuana on heart rate, drug ratings and task performance by humans. *Behavioural Pharmacology*. 4:167-178.

D.101- Kelly, T.H., Foltin, R.W., Mayr, M.T., and Fischman, M.W. (1994). Effects of D9-tetrahydrocannabinol and social context on marijuana self-administration by humans. *Pharmacology, Biochemistry and Behavior*. 49:763–768.

*D.102- Kirk et al., 1999 (same as C.100-).

D.103- Klein, T.W., Lane, B., Newton, C.A. and Friedman, H. (2000). The cannabinoid system and cytokine network. *Proceedings of the Society for Experimental Biology and Medicine*. 225(1):1–8.

D.104- Kurup, V.P., Resnick, A., Kagen, S.L., Cohen, S.H., Fink, J.N. (1983). Allergenic fungi and actinomycetes in smoking materials and their health implications. *Mycopathologia*. 82(1):61–4.

*D.105- Kurzthaler et al., 1999 (same as C.101-).

*D.106- Lane et Phillips-Bute, 1998 (same as C.102-).

*D.107- Lemberger et al., 1972 (same as C.105-).

*D.108- Liguori et al., 1998 (same as C.107-).

D.109- Lile, J.A. (2006). Pharmacological determinants of the reinforcing effects of psychostimulants: relation to agonist substitution treatment. *Experimental Clinical Psychopharmacology*. 14(1):20–33.

D.110- Lukas, S.E., Mendelson, J.H., and Benedikt, R. (1995). Electroencephalographic correlates of marijuana-induced euphoria. *Drug and Alcohol Dependence*. 37:131– 140.

*D.111- Lyons et al., 2004 (same as C.109-).

*D.112- Mackie et al., 1995 (same as C.110-).

*D.113- Maldonado, 2002 (same as C.111-).

D.114- Maneuf, Y.P., and Brotchie, J.M. (1997). Paradoxical action of the cannabinoid WIN 55212–2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. *British Journal of Pharmacology*. 120: 1397–1398.

D.115- Mansbach, R.S., Rovetti, C.C., Winston, E.N., and Lowe J.A. (1996). Effects of the cannabinoid CB1 receptor antagonist SE14176A on the behavior of pigeons and rats. *Psychopharmacology*. 124(4):315–322.

*D.116- Martellotta et al., 1998 (same as C.113-).

D.117- Martin, B.R. and Hall, W. (1997, 1998). The health effects of cannabis: key issues of policy relevance. *Bulletin on Narcotics XLIX & L (1 &2)*: 85–116.

*D.118- Martin et al., 1999 (same as C.115-).

*D.119- Mathers et al., 1992 (same as C.114-).

D.120- Mathew, R.J., Wilson, W.H., Davis, R. (2003). Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. *Pharmacology, Biochemistry and Behavior*. 75:309–318.

*D.121- Matsuda et al., 1990 (same as C.116-).

D.122- McGrath, J., Welham, J., Scott, J., Varghese, D., Degenhardt, L., Hayatbakhsh, M.R., Alati, R., Williams, G.M., Bor, W., Najman, J.M. (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. *Archives of General Psychiatry*. 67(5):440–7.

D.123- McLaren, J., Swift, W., Dillon, P., Allsop, S. (2008). Cannabis potency and contamination: a review of the literature. *Addiction*. 103(7):1100–9.

D.124- McPartland, J.M. (1994). Microbiological contaminants of marijuana. *Journal of the International Hemp Association*. 1: 41–44.

D.125- McPartland, J.M. (2002). Contaminants and adulterants in herbal cannabis. In In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press.

D.126- Mechoulam, R. (1973). Marijuana: Chemistry, pharmacology, metabolism, and clinical effects. NY: Academic Press.

D.127- Medina, K.L., Hanson, K.L., Schweinsburg, A.D., Cohen-Zion, M., Nagel, B.J., Tapert, S.F. (2007). Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. *Journal of the International Neuropsychology Society*. 13(5):807–20.

D.128- Mello, N. K. (1983). A behavioral analysis of the reinforcing properties of alcohol and other drugs in man. In B. Kissin & H. Begleiter (Eds.), *The pathogenesis of alcoholism, biological factors* (Vol. 7, pp. 133–198). New York: Plenum Press.

D.129- Mello, N.K. (1989). Drug self-administration procedures: Alcohol and marijuana. In NIDA Research Monograph 92: *Testing for Abuse Liability of Drugs in Humans*. 92:147–170.

D.130- Mendelson, J.H. and Mello, N.K. (1984). Reinforcing properties of oral D9-tetrahydrocannabinol, smoked marijuana and nabilone: Influence of previous marijuana use. *Psychopharmacology*. 83:351–356.

*D.131- Messinis et al., 2006 (same as C.119-).

D.132- Moore, T.H., Zammit, S., Lingford-Hughes, A., Barnes, T.R., Jones, P.B., Burke, M., Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 370(9584):319–28.

D.133- Murray, J.E., Bevins, R.A. (2010). Cannabinoid conditioned reward and aversion: behavioral and neural processes. *ACS Chemical Neuroscience*. 1(4):265–278.

D.134- National Institutes of Health (NIH). Workshop on the medical Utility of Marijuana, February 19–20, 1997. (www.nih.gov/news/medmarijuana/MedicalMarijuana.htm) Paris, M. and Nahas, G.G. (1984). Botany: the unstabilized species. In: Nahas G.G. (Ed.) *Marihuana in science and medicine*. NY: Raven Press, pp. 3–36.

D.135- Paris, M. and Nahas, G.G. (1984). Botany: the unstabilized species. In: Nahas G.G. (Ed.) *Marihuana in science and medicine*. NY: Raven Press, pp. 3–36.

D.136- Perez-Reyes, M., Simmons, J., Brine, D., Kiel, G.L., Davis, K.H., Wall, M.E. (1976). Rate of penetration of deltatetrahydrocannabinol to the brain of mice. In: Nahas G, Paton WDM, Idanpaan-Heikkila JE (Eds), *Marihuana: Chemistry, biochemistry, and cellular effects*. Springer-Verlag: New York, pp 179–185.

D.137- Perez-Reyes, M., Timmons, M.C., Lipton, M.A., Davis, K.H., and Wall, M.E. (1972). Intravenous injection in man of 9- tetrahydrocannabinol and 11-OH-9- tetrahydrocannabinol. *Science*. 177(49):633–635.

D.138- Perio, A., Rinaldi-Carmona, M., Maruani, J., Barth, F., LeFur, G., and Soubrie, P. (1996). Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. *Behavioural Pharmacology*. 7: 65–71.

*D.139- Piomelli, 2005 (same as C.126-).

D.140- Pope, G.H. Jr., Gruber, A.J., Hudson, J.I., Huestis, M.A., and Yurgelun-Todd, D. (2002). Cognitive measures in long-term cannabis users. *Journal of Clinical Pharmacology*. 42(11 Suppl):41S–47S.

*D.141- Pope et al., 2003 (same as C.127-).

*D.142- Ramaekers et al., 2004 (same as C.128-).

D.143- Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., and Goodwin, F.K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *Journal of the American Medical Association*. 264(19):2511–2518.

D.144- Robbe, H.W.J., and O'Hanlon, J.F., (1999). Marijuana, alcohol and actual driving performance. Dot HS 808 939. US Department of Transportation National Highway Traffic Safety Administration, Maastricht, The Netherlands.

*D.145- Rodriguez de Fonseca et al., 1994 (same as C.129-).

*D.146- Ross and El Sohly, 1995 (same as C.130-).

D.146- Roth, M.D., Arora, A., Barsky, S.H., Kleerup, E.C., Simmons, M. and Tashkin, D.P. (1998). Airway inflammation in young marijuana and tobacco smokers. *American Journal of Respiratory and Critical Care Medicine*. 157:928–937.

*D.147- Roth et al., 2005 (same as C.131-).

*D.148- Sanudo-Pena et al., 1997 (same as C.132-).

*D.149- Schiffman et al., 2005 (same as C.134-).

D.150- Schuster, C.R. and Thompson, T. (1969). Administration of and behavioral dependence on drugs. *Annual Review of Pharmacology*. 9: 483–502.

*D.151- Sidney, 2002 (same as C.135-).

D.152- Solinas, M., Panlilio, L.V., Justinova, Z., Yasar, S., Goldberg, S.R. (2006). Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. *Nature Protocols*. 1(3):1194–206.

*D.153- Solowij et al., 2002 (same as C.136-).

D.154- Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2009). Results from the 2008 National Survey on Drug Use and Health: National Findings (NSDUH Series: H–34, DHHS Publication No. SMA 08–4343). Rockville, MD.

D.155- Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2009). Treatment Episode Data Set (TEDS). Highlights—2007. National Admissions to Substance Abuse Treatment Services, DASIS Series: S–45, DHHS Publication No. (SMA) 09–4360, Rockville, MD.

D.156- Tashkin, D.P., Coulson, A.H., Clark, V.A., Simmons, M., Bourque, L.B., Duann, S., Spivey, G.H., and Gong, H. (1987). Respiratory symptoms and lung function in habitual, heavy

smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. *American Review of Respiratory Disease*. 135:209–216.

*D.157- Tashkin et al., 2006 (same as C.143-).

D.158- Taylor, D.N., Wachsmuth, I.K., Shangkuan, Y.H., Schmidt, E.V., Barrett, T.J., Schrader, J.S., Scherach, C.S., McGee, H.B., Feldman, R.A., Brenner, D.J. (1982). Salmonellosis associated with marijuana: a multistate outbreak traced by plasmid fingerprinting. *New England Journal of Medicine*. 306(21):1249–53.

D.159- Thomas, H. (1993). Psychiatric symptoms in cannabis users. *British Journal of Psychiatry*. 163:141–149.

*D.160- Thornicroft, 1990 (same as C.144-).

D.161- Thornicroft, G. (1990). Corrigendum. *British Journal of Psychiatry*. 157:460.

*D.162- Twitchell et al., 1997 (same as C.145-).

D.163- Ungerleider, J.T., Andrysiak, T., Tashkin, D.P., Gale, R.P. (1982). Contamination of marijuana cigarettes with pathogenic bacteria-possible source of infection in cancer patients. *Cancer Treatment Reports*. 66(3):589–91.

*D.164- van Os et al., 2002 (same as C.148-).

*D.165- Vandrey et al., 2005 (same as C.147-).

*D.166- Wagner et al., 1998 (same as C.151-).

D.167- Weil, A.T. (1970). Adverse reactions to marijuana. Classification and suggested treatment. *New England Journal of Medicine*. 282 (18):997–1000.

*D.168- Wiley et al., 1995 (same as C.153-).

*D.169- Yanagita, 1979-1980 (same as C.155-).

*D.170- Zhang et al., 1999 (same as C.156-).

E- Denial of Petition To Initiate Proceedings To Reschedule Marijuana; Proposed Rule, 76 Federal Register 131 (8 July 2011), pp 40552- 40589